Investors worry about Lundbeck's future, analysts remain optimistic

A disappearing pipeline and the fear of potential overpriced acquisitions concern Lundbeck's investors. However, analysts maintain optimism.

Photo: Jens Dresling

Stock in Danish pharmaceutical company Lundbeck has been falling behind on Nasdaq Copenhagen for several years. Now, investors are concerned about the company's future.

Analysts, however, see the potential for double-digit growth of company equity, reports domestic business daily Børsen.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs